News

The Pharma Letter1d
FDA removes REMS requirement from Idorsia’s Tryvio label
Swiss biopharma Idorsia (SIX: IDIA) has received approval from the US Food and Drug Administration for an updated label on ...
Idorsia Pharmaceuticals Ltd: US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
Idorsia Ltd (SIX: IDIA) today announced that the US Food & Drug Administration (FDA), after having released TRYVIO from its REMS (Risk Evaluation and Mitigation Strategy) ...
The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension
Aprocitentan, on top of background therapy, showed clinically meaningful and durable blood pressure (BP) reduction and a decrease in proteinuria ...
The Manila Times1d
US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement
Michael Moye, President and General Manager of Idorsia US, commented: "The fact that the FDA has expedited the approval of ...